论文部分内容阅读
天津市新药安全评价研究中心是在天津药物研究院新药评价中心的基础上注册成立的独立法人研究机构。中心凝聚了刘昌孝院士领衔的92人科研团队,先后承担国家“十五”、“十一五”、“十二五”的药代平台、GLP安评平台以及药效平台的建设任务,是目前我国开展新药非临床成药性综合评价的技术领先单位。
Tianjin New Drug Safety Evaluation Research Center is an independent legal person research institution incorporated on the basis of the New Drug Evaluation Center of Tianjin Institute of Materia Medica. The center has gathered 92 scientific research teams led by Academician Liu Changxiao and successively undertaken the drug platform, GLP safety evaluation platform and efficacy of the national “十五 ”, “Eleventh Five-Year” and “Twelfth Five-Year Plan” Platform construction tasks, is China’s current non-clinical drug development of new comprehensive evaluation of the leading technology unit.